The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Assessment of ctDNA somatic homologous recombination deficiency (HRD) in triple-negative breast cancer (TNBC) from SWOG S1416 trial.
 
Shane Stecklein
Honoraria - Almac Diagnostics
Consulting or Advisory Role - McKinsey & Company
Research Funding - Natera
 
William Barlow
Research Funding - AstraZeneca (Inst); Merck (Inst)
 
Jill Tsai
Employment - Guardant Health
Stock and Other Ownership Interests - Guardant Health; Guardant Health (I); Guardant Health (Inst)
Research Funding - Guardant Health
Travel, Accommodations, Expenses - Guardant Health
 
Arielle Yablonovitch
Employment - Guardant Health
Stock and Other Ownership Interests - Guardant Health
Patents, Royalties, Other Intellectual Property - Patent application filed with Guardant Health
Travel, Accommodations, Expenses - Guardant Health
 
Eve Rodler
No Relationships to Disclose
 
Peter Kuhn
Stock and Other Ownership Interests - Cansera; Earli; Epic Sciences; forbie; Sampling Human
Consulting or Advisory Role - Quest Diagnostics
Research Funding - Abbvie; Amgen; Daiichi Sankyo; Fluidigm; Gilead Sciences; Kite, a Gilead company; Lilly; Novartis
Patents, Royalties, Other Intellectual Property - HDSCA liquid biopsy technology developed in the Kuhn laboratory initially at The Scripps Research Institute and subsequently at the University of Southern California and related patents have been licensed for commercial development to Epic Sciences.; Patent 62/783,921: "System and Method for Determining Human Performance". Systems and methods in human performance to determine whether a cancer patient will need unplanned medical care during cancer therapy.
 
James Hicks
No Relationships to Disclose
 
Harsh Pathak
No Relationships to Disclose
 
Daniel Hayes
Stock and Other Ownership Interests - Cellworks; InBiomotion; Xilis
Consulting or Advisory Role - Artera; Arvinis; bioTheranostics; BioVica; Cellworks; Centrix; Cepheid; Delphi Diagnostics; Epic Sciences; Exact Sciences; Manta Cares; microbiologics; MIlagen; Spotlight Diagnostics; Strata Oncology; Stratipath; xilis
Research Funding - Angle (Inst); AstraZeneca (Inst); Cepheid/Danaher (Inst); Menarini Silicon Biosystems (Inst)
Patents, Royalties, Other Intellectual Property - Circulating Tumor Cell Capturing Techniques and Devices. Patent No.: US 8,951,484 B2. Date of Patent: Feb. 10, 2015. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/co-inventor.; Diagnosis and Treatment of Breast Cancer. Patent No. US 8,790,878 B2. Date of Patent: Jul. 29, 2014. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/co-inventor.; Royalties from licensed technology.; Title: A method for predicting progression free and overall survival at each follow-up timepoint during therapy of metastatic breast cancer patients using circulating tumor cells. Patent no. 05725638.0-1223-US2005008602.
Other Relationship - Cancer Expert Now; UpToDate
 
James Rae
No Relationships to Disclose
 
Gabriel Hortobagyi
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Novartis; Seagan
 
Alastair Thompson
Employment - Lilly (I)
Stock and Other Ownership Interests - Lilly (I)
 
Andrew Godwin
Employment - University of Kansas Health System
Stock and Other Ownership Interests - Exokeryx
Honoraria - Sinochips Diagnostics
Research Funding - Predicine (Inst); VITRAC Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Provisional - US Patent number 63/391,657 entitled “Extracellular Vesicle Proteomic Biomarker Panel for Ovarian Cancer Screening and the Early Detection of Disease”. (Inst); Provisional - US Patent number 63/496,270 entitled “Treatment of Neoplasm by Inhibiting KIF15”. (Inst); Provisional Patent application entitled - "WJMSC-Derived Small Extracellular Vesicle (sEVs) Enhance T Cell Suppression Through Checkpoint PD-L1" - Dr. Joseph McGuirk (applicant) (Inst)
 
Lajos Pusztai
Stock and Other Ownership Interests - Ataraxis
Honoraria - Agendia; AstraZeneca; Bristol-Myers Squibb; Merck @ Co; natera; Radionetics
Consulting or Advisory Role - Agendia; AstraZeneca; Bristol Myers Squibb; Merck; Natera; Personalis; Radionetics
Research Funding - Agendia (Inst); AstraZeneca (Inst); Bristol Myers Squibb (Inst); Exact Sciences (Inst); Menarini (Inst); Merck (Inst); Natera (Inst); Personalis (Inst); Pfizer (Inst)
(OPTIONAL) Uncompensated Relationships - Caris Life Sciences; Foundation Medicine
 
Priyanka Sharma
Stock and Other Ownership Interests - Amgen; Gilead Sciences (I); Johnson & Johnson/Janssen; Pfizer (I); Roche/Genentech (I); Sanofi
Consulting or Advisory Role - AstraZeneca; Boston Scientific (I); Cipla (I); Gilead Sciences; GlaxoSmithKline; Lilly; Merck; Novartis; Pfizer; Salient Pharmaceuticals (I); Sanofi; Stemline Therapeutics
Research Funding - Bristol-Myers Squibb (Inst); Gilead Sciences (Inst); Merck (Inst); Novartis (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate